Inhibikase Therapeutics, Inc.
IKT
$1.66
-$0.01-0.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.75% | -4.96% | -106.47% | -99.93% | -194.19% |
| Total Depreciation and Amortization | -- | -100.00% | 259.09% | 266.67% | 92.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -46.91% | -39.19% | 2,239.12% | 12,441.69% | 15,320.60% |
| Change in Net Operating Assets | -103.80% | 136.28% | -389.33% | 453.64% | 83.77% |
| Cash from Operations | -193.89% | -40.60% | -117.01% | -10.28% | -6.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -482.03% | 99.75% | -1,237.96% | 287.06% | 736.14% |
| Cash from Investing | -482.27% | 99.75% | -1,237.96% | 287.06% | 735.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 8.52% | 37.86% | -99.01% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 8.91% | -173.68% | -99.02% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -628.86% | 81.64% | -1,716.52% | 486.73% | 348.84% |